Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.

ABSTRACT:

Introduction

HER2 overexpression/amplification is identified in up to 40% of uterine serous carcinomas (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents failed to show significant responses. FDA-approved HER2 assays target only the protein's intracellular domain (ICD) and not the extracellular domain (ECD). Previous quantitative studies in breast cancer by our group have shown that ICD of HER2 is expressed in some cases that do not express the HER2 ECD. We measured HER2 ICD and ECD in USC and OSC samples, and determined their relationship with clinico-pathologic characteristics and survival.

Methods

We measured HER2 ICD and ECD levels in 2 cohorts of USC and OSC comprising 102 and 175 patients, respectively. HER2 an

SUBMITTER: Carvajal-Hausdorf DE 

PROVIDER: S-EPMC5941302 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature